Evidence Hub

Emergence of amoxicillin resistance in refractory Helicobacter pylori infection

Lin CY, Kuo CJ, Lai CH, Lin WP, Chen CW, Lin WR, Chang ML, Ho YP et al.

Therapeutic advances in gastroenterology, 2025

144 participants

Abstract

Objectives: This study investigated temporal changes in resistance patterns among treatment-refractory Helicobacter pylori infections in Taiwan.

Background: Antibiotic resistance in H. pylori is a growing global concern.

Design: We retrospectively analyzed adult patients at Linkou Chang Gung Memorial Hospital (2018-2024) with ⩾2 prior eradication failures and confirmed active infection via [13C]-urea breath test.

Methods: Gastric biopsy specimens were cultured, and antimicrobial susceptibility testing was performed using the Epsilometer test for amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, rifabutin, ciprofloxacin, and moxifloxacin. Breakpoints were defined according to the European Committee on Antimicrobial Susceptibility Testing.

Results: Among 144 patients (mean age 57.1 ± 10.8 years; 27.8% male), 88 were culture positive (61.1%), yielding 109 isolates. Resistance rates were high for clarithromycin (89.9%), levofloxacin (86.2%), metronidazole (71.6%), and ciprofloxacin (87.2%), while tetracycline resistance was 15.6%. A temporal trend analysis revealed a marked and statistically significant increase in amoxicillin resistance (odds ratio per year, 1.60; 95% confidence interval, 1.31-1.96; p < 0.001), while resistance to other key antimicrobials remained persistently high but stable.

Conclusion: In refractory H. pylori infection, there is persistently high resistance to clarithromycin, fluoroquinolones, and metronidazole, with a notable surge in…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free